Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma

Sponsor
National Cancer Centre, Singapore
Study ID
NCT03033446
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
21 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • Y-90 Radioembolization — RADIATION
    Dose of Yttrium-90 is determined based on BSA, size of liver tumor, and dose modifications required for percent lung shunting between 10-20% on the Tc-99MMA scan
  • Nivolumab — DRUG
    21 days after Radioembolization, 240mg of IV Nivolumab over 30 minutes will be administered every 2 weeks

Study Details

The purpose of this study is to evaluate the effect of liver-localised radioembolization and nivolumab on liver cancer.

Key Dates

Start date
Dec 20, 2016
Status verified
May 2026
Primary completion
Aug 31, 2019
Completion
Apr 26, 2023

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Y90-Radioembolization and Nivolumab

Primary Outcome Measure

Response Rate [ Time Frame: Tumour assessment at 8 weeks ]

Related Studies